|
|
||||||||
Institute for Surgical Research, Klinikum Grosshadern, Ludwig-Maximilians-University, 81377 Munich, Germany
| |
ABSTRACT |
|---|
|
|
|---|
Hemoglobin-based oxygen carriers have been suggested to enhance the formation of oxygen free radicals, especially under conditions of ischemia-reperfusion (I/R), in which activation and adhesion of leukocytes play a pivotal role for propagation of reperfusion injury. This study investigates the effects of the hemoglobin-based oxygen carrier diaspirin-cross-linked hemoglobin (DCLHb) in an I/R model of hamster striated skin muscle. The dorsal skinfold chamber model in the awake Syrian golden hamster was used for analysis of the microcirculation and local tissue PO2 in striated skin muscle utilizing the technique of intravital fluorescence microscopy and a multiwire platinum surface (Clark type) electrode. Measurements were made before 4 h of pressure-induced ischemia and at 0.5, 2, and 24 h of reperfusion. Animals were treated with 5 ml/kg body wt of either 10% DCLHb (n = 8), 6% Dextran 60 (Dx-60; 60 kDa, n = 8), or 0.9% NaCl (n = 7), which was given intravenously 15 min before reperfusion. In animals treated with DCLHb or Dx-60, a significant decrease of leukocytes rolling along and sticking in postcapillary venules, associated with a recovery of functional capillary density and red blood cell velocity, was observed compared with saline-treated controls. In the early reperfusion period (0.5 h), DCLHb and Dx-60 efficiently restored local tissue PO2, whereas tissue PO2 decreased from 18.3 ± 1.9 to 15.3 ± 5.3 mmHg in 0.9% NaCl-treated animals. Electron microscopic analysis of the postischemic tissue at 24 h of reperfusion revealed markedly reduced tissue damage in animals treated with DCLHb compared with Dx-60 or isotonic saline. These results indicate that DCLHb attenuates postischemic reperfusion injury of striated skin muscle, presumably through alterations of leukocyte-endothelial cell interactions.
hemoglobin-based oxygen carriers; blood substitutes; local tissue partial pressure of oxygen; leukocyte-endothelial cell interaction; multiwire surface electrode
| |
INTRODUCTION |
|---|
|
|
|---|
THE DEVELOPMENT of hemoglobin-based oxygen carriers as red blood cell (RBC) substitutes has been hampered by unwanted side effects such as nephrotoxicity, complement activation, and risk of transmission of infectious diseases. These impediments have recently been eliminated through significant technical improvements in the production and purification procedures of stroma-free hemoglobin, on the one hand, and chemical modification procedures of the hemoglobin molecule, on the other hand.
Diaspirin-cross-linked hemoglobin (DCLHb) is a stroma-free hemoglobin
solution characterized by an intramolecular cross-link between the
99Lys of the
-chains (2). DCLHb
has been shown to function as an oxygen carrier, particularly under
conditions of ischemia-reperfusion (I/R) (3, 13). However,
there is concern that hemoglobin-based oxygen carriers could enhance
formation of oxygen free radicals, particularly during reperfusion of
postischemic tissues (5). One of the potential mechanisms is the
release of free iron from the prosthetic heme group, thus promoting the
formation of hydroxyl radicals via the Haber-Weiss reaction by acting
as a Fenton reagent (24). This would lead to an enhancement of lipid
peroxidation and leukocyte-endothelial cell interaction, activation of
the inflammatory cascade, release of cytosolic enzymes, and destruction of postischemic tissues (12).
To date, there is no in vivo evidence to suggest that an oxygen-carrying blood substitute is a potential source of oxygen free radical-induced leukocyte activation and adhesion associated with reperfusion injury. The aim of this study therefore was to analyze the effects of DCLHb as an oxygen-carrying blood substitute and as a hemoglobin-based therapeutic on the local microcirculation and tissue PO2 after severe ischemia followed by reperfusion.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Hemoglobin solution.
DCLHb
[99
-bis(3,5-dibromosalicyl)fumarate
hemoglobin, lot no. HBXR-92-268-42793] was
provided by Baxter Healthcare (Deerfield, IL). The characteristics of
the hemoglobin solution have been described previously (20).
Animal model. Syrian golden hamsters weighing 50-70 g (Charles River, Sulzfeld, Germany) were kept under acclimated conditions with free access to tap water and pellet food ad libitum. Experiments were approved by the local ethics committee and performed according to the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals (DHHS, revised 1985). The dorsal skinfold chamber in awake Syrian golden hamsters (19) was used for investigation of the microcirculation and local PO2. The chamber implantation was performed 48-72 h before the experiment under ketamine-xylazine anesthesia (130 and 20 mg/kg body wt ip, respectively). Polyethylene catheters (Portex, Hythe, UK) were inserted into the jugular vein and carotid artery for monitoring of mean arterial pressure (MAP), heart rate (HR), and arterial blood gases.
Experimental protocol. For measurement of tissue PO2 and intravital microscopic analysis, animals were randomly assigned to three different treatment groups. After a recovery period of at least 48 h, baseline values were recorded. Animals were subjected to a period of 4 h of pressure-induced ischemia, which was applied using an adjustable screw clamp with a transparent silicon pad, as previously described (19).
Animals of group A (n = 7) received 5 ml/kg body wt iv of isotonic saline (0.9% NaCl) 15 min before reperfusion; animals of group B (n = 8) received the same dose of 6% Dextran 60 (Dx-60; 60 kDa; Schiwa, Germany) as an isooncotic control; and animals of group C (n = 8) were treated with 5 ml/kg body wt 10% DCLHb. Measurements were made before ischemia and at 0.5, 2, and 24 h of reperfusion. Tissue oxygen measurement. Measurement of local tissue PO2 in the chamber tissue was performed using a Clark-type oxygen multiwire platinum electrode (MDO electrode, Eschweiler, Kiel, Germany) as described by Kessler and Lübbers (see Ref. 11). The electrode was connected to a 15-channel computer-assisted amplifier (MIB, Steindorf, Germany). At the preset time points of investigation, the cover glass of the transparent chamber was gently removed, and the tissue was superfused with isotonic saline solution (Braun, Melsungen, Germany) at room temperature. The MDO electrode was placed on the tissue with a microstep motor as previously described (20). The MDO electrode contains eight single platinum wires in an asymmetric distribution, each measuring individual tissue PO2 values within an approximately spherical volume of 25 µm3. An integrated temperature probe allowed continuous measurement of local tissue temperature for on-line correction of the tissue PO2 values. A period of 5-6 min was needed for collection of 100-120 single-tissue PO2 values, which was achieved by moving the electrode via a step motor. Tissue PO2 was determined within the underlying tissue according to the experimental protocol at 0.5, 2, and 24 h of reperfusion. Tissue PO2 values were grouped in classes of 5 mmHg and plotted vs. percent frequency of occurrence (see Fig. 4). Spatial distribution of tissue PO2 values allows the assessment of variations of tissue PO2 ranging from values of zero to values representing arteriolar tissue PO2 in a highly reproducible manner (16). Intravital microscopy. Analysis of the microvascular parameters in the striated skin muscle of the hamster was performed with an intravital microscope (Zeiss, Jena, Germany) connected to a computer-controlled stepping motor for exact repeated measurements of the identical vessel segments. For visualization of leukocyte-endothelial cell interactions, leukocytes were stained by intravenous injection of 0.5% rhodamine 6G (0.15 mg/kg body wt, Sigma Chemicals, Deisenhofen, Germany). Animals were injected with 15 ml/kg body wt of an intravenous bolus of FITC-Dx (150 kDa; Pharmacia, Uppsala, Sweden) for analysis of the macromolecular leakage of microvessels and the RBC velocity. Video images were recorded on videotapes and evaluated off-line by a computer-assisted microcirculation analysis system (CapImage, Dr. H. Zeintl, Heidelberg, Germany). Parameters were assessed as follows. 1) Functional capillary density (FCD) was defined as the length of RBC-perfused capillaries in the striated skin muscle per observation area (cm/cm2). 2) Leukocyte-endothelial cell interactions were determined by quantitative analysis of the number of nonadherent leukocytes passing per minute (NAL/min), the fraction of rolling leukocytes (%), and the number of firmly sticking leukocytes per endothelial surface (stickers/mm2). The rolling fraction was calculated using the formula
|
| |
RESULTS |
|---|
|
|
|---|
Systemic parameters. HR and MAP remained unchanged in the NaCl- and Dx-60 treated groups. MAP increased after infusion of DCLHb by 21% above baseline at 0.5 h of reperfusion, and this higher blood pressure was significantly different from the value in 0.9% NaCl-treated and Dx-60-treated animals (Table 1). No significant changes of HR were observed among treatment groups.
|
Microcirculatory parameters. Venular and arteriolar diameters are listed in Table 2. There were no significant changes in arteriolar diameters after reperfusion of the postischemic muscle, whereas initially reperfusion led to an increase in venular diameter in all three groups.
|
|
2 after 2 h
of reperfusion. These changes were significantly attenuated in the two
treatment groups. It is noteworthy that the reduction of leukocyte
rolling and sticking was more pronounced after treatment with DCLHb
compared with Dx-60. Leakage of the fluorescent marker FITC-Dx (150 kDa) was significantly reduced at 24 h of reperfusion in DCLHb-treated
animals compared with Dx-60 treatment (Fig. 1).
|
|
Local tissue PO2. No significant changes were found in any treatment group with respect to local tissue PO2 (Fig. 3). However, there was a slight reduction in mean tissue PO2 values by 16% (from 18.2 ± 1.9 mmHg at baseline to 15.3 ± 5.3 mmHg at 0.5 h of reperfusion) in the 0.9% NaCl control, which was accompanied by a left shift of the PO2 distribution, i.e., frequency of reading (Fig. 4). Measurements of tissue PO2 after pretreatment with Dx-60 and DCLHb showed that in both experimental groups tissue PO2 was effectively restored on reperfusion (Fig. 4). Analysis of tissue PO2 distribution indicated a left shift in tissue PO2 values to hypoxic values (0-10 mmHg) in 0.9% NaCl-treated animals only, whereas such a shift was not observed in DCLHb or Dx-60 treatment groups (Fig. 4).
|
Histomorphology. Analysis of the electron microscopic cross-sections revealed destruction of striated skin muscle architecture, with focal myolysis and formation of vacuoles and edema within the muscle fibers as signs of ischemic tissue damage at 24 h of reperfusion in the 0.9% NaCl control group (Fig. 5A). The swelling of endothelial cells in capillaries was accompanied by formation of vacuoles within these cells. A prominent feature of these sections was obstruction of capillaries by RBC. Treatment with Dx-60 attenuated the disintegration of the muscle architecture and reduced vacuolar degeneration, but there was still massive endothelial swelling in capillaries, causing near complete obstruction of the capillary lumina (Fig. 5B). The postischemic tissue damage was most effectively reduced in DCLHb-treated animals (Fig. 5C). Only rare formation of vacuoles and myolysis and virtually no endothelial swelling in capillaries was found when compared with Dx-60 or 0.9% NaCl treatment.
|
| |
DISCUSSION |
|---|
|
|
|---|
The findings of the present study provide the first in vivo evidence that the hemoglobin-based oxygen carrier DCLHb reduces leukocyte-endothelial cell interactions and macromolecular leakage in venules of striated skin muscle after 4 h of pressure-induced ischemia followed by reperfusion. DCLHb improved both functional capillary density and local tissue oxygenation of striated skin muscle after I/R; these findings were corroborated by electron microscopic demonstration of a reduction of postischemic reperfusion injury.
The dorsal skinfold chamber preparation in the awake Syrian golden hamster is a suitable model to study the pathophysiology of I/R without unwanted side effects of anesthetic drugs on the microcirculation and local tissue oxygenation (19). The model permits assessment of the therapeutic effects of pharmacological agents on postischemic reperfusion injury. The tissue PO2 distribution histogram obtained from the hamster dorsal skinfold has been shown to be highly reproducible and of predictive value for I/R injury (20). Four hours of pressure-induced ischemia followed by reperfusion was identified as the crucial ischemia time for induction of severe tissue damage in striated skin muscle (9). Therefore, the model is well suited to study the therapeutic efficacy of pharmacological agents for the treatment of I/R injury or, conversely, the properties of drugs with the potential to exacerbate reperfusion injury.
Various studies have proven the oxygen-carrying and volume-substituting properties of DCLHb when used as a RBC substitute. DCLHb is effective in restoring macro- and microcirculatory parameters (18) as well as tissue oxygenation (20, 22) after severe hemorrhagic shock. Despite the favorable effects of DCLHb in the treatment of hemorrhagic shock, a condition characterized by partial global ischemia (12), the potential property of hemoglobin-based oxygen carriers to catalyze lipid peroxidation (24) is of major concern, particularly under conditions of I/R.
Motterlini et al. (17) studied the effects of stroma-free hemoglobin
solutions on the oxidative-stress response of vascular endothelial
cells in vitro. HbA0 as well as

-cross-linked Hb were capable of inducing hydroxyl radical
formation. Faassen et al. (5) have shown in vitro that purified
hemoglobin induces lipid peroxidation; however, this effect was
dependent on temperature and duration of storage of hemoglobin (5).
Dawidson et al. (4) demonstrated deleterious effects of unmodified
stroma-free hemoglobin on the intestine after resuscitation of rats.
The authors proposed the release of free iron ions from the prosthetic
heme with ensuing generation of the cytotoxic hydroxyl radical as the underlying mechanism (24) through further activation of
leukocyte-endothelial cell interactions, which contribute to impairment
of microvascular perfusion and tissue oxygenation in the target
organ. Although not proven in vivo, these mechanisms may
lead to the exacerbation of reperfusion injury in postischemic tissue.
Contradictory to observations of these undesirable effects of unmodified stroma-free hemoglobin solutions are recent findings from other investigators using purified and heat-pasteurized DCLHb. In contrast to the work by Dawidson et al. (4), it has been reported that DCLHb is efficacious in restoring intestinal mucosal oxygenation and preserving villous architecture after hemorrhagic shock in rats (6). Cole et al. (3) found a significant reduction of brain injury and cerebral edema formation, as assessed by histomorphology after focal cerebral ischemia in rats previously hemodiluted with DCLHb (3). Cerebral blood flow was significantly higher in DCLHb-treated animals compared with albumin-treated animals. McKenzie et al. (13) investigated the effects of coronary perfusion with DCLHb during angioplasty. Myocardial function and S-T segment depression, early signs of ischemia, were attenuated during temporary occlusion of coronary arteries in swine infused with DCLHb. In a separate model of coronary I/R, McKenzie et al. (13) observed that DCLHb infusion before reperfusion reduced infarct size, decreased reperfusion arrhythmias, and improved regional myocardial function in swine. Pincemail et al. (21) directly studied the generation of free radicals in a model of renal ischemia in rabbits by means of electron-spin resonance spectroscopy. Compared with control, no exacerbation of free radical generation was found after exchange transfusion with DCLHb. These reports are in agreement with our in vivo findings that the modified hemoglobin DCLHb does not enhance postischemic reperfusion injury. Moreover, our data suggest that DCLHb can be considered as a therapeutic agent for treatment of I/R-induced microvascular disturbances. The reduction of leukocyte-endothelial cell interactions, the reduction of macromolecular leakage of FITC-Dx, and the improvement of muscle histomorphological integrity after reperfusion imply a protective action of DCLHb in I/R.
Like other investigators (8), we too have encountered an elevation of MAP after administration of DCLHb. The increase of MAP after the infusion of hemoglobin is partly mediated via scavenging of NO/endothelium-derived relaxing factor, an increase in endothelin release (25), and/or sensitization of catecholamine receptors (8). Despite the pressor effects of DCLHb in vitro (7), no vasoconstriction of the arterioles analyzed (15-80 µm) was observed after administration of DCLHb in this I/R model. Similar results were reported by Sharma and Gulati (26), who showed that administration of DCLHb resulted in an increase in blood flow to the skin, whereas blood flow to the musculoskeletal system remained constant (26). These findings suggest the existence of regional differences in the vascular response to DCLHb. The initial nonsignificant increase of RBC velocity in our study at 0.5 h after reperfusion in DCLHb-treated animals may be attributed to an initial constriction of arterioles in the early reperfusion phase. A velocity increase of similar degree has been described to occur in the same model also under physiological conditions, with an immediate onset in the first minutes after intravenous injection of DCLHb (18). This effect, however, was transient. Our studies suggest that the vasoconstrictor effect, probably accounting for a longer-lasting increase in MAP, documented for arteries in vitro does not occur in small arterioles and does not compromise blood flow to the skin under physiological or pathophysiological conditions. Kumar (10) reported that resuscitation with DCLHb improved perfusion of kidney and brain of hemorrhaged rats.
FCD is an indicator of tissue perfusion and correlates with the degree
of reperfusion injury, as assessed in different tissues (19). A
reduction of FCD, also known as the "no-reflow" phenomenon, is
thought to be the pivotal mechanism contributing to I/R injury (15).
The present study confirms the beneficial effect of Dx-60 in enhancing
FCD under conditions of I/R, as reported by other investigators (14,
19). DCLHb restored microvascular perfusion more efficiently than
Dx-60, as shown by results obtained with intravital and electron
microscopy. Tsai et al. (29) investigated the effect of

-Hb compared with Dextran-70 (Dx-70) on FCD and oxygen delivery after isovolemic hemodilution to a systemic hematocrit of 30% of control in the hamster dorsal skinfold chamber in the absence of I/R. Their study found a gradual reduction of FCD but no
notable differences in oxygen-carrying capacity after hemodilution either with Dx-70 or 
-Hb. Recent findings from our own laboratory showed a significant decrease of FCD after isovolemic hemodilution to a
hematocrit of 30% with both DCLHb (18) and ultrapurified bovine
hemoglobin (1) in the same model. Because FCD describes the length of
RBC-perfused capillaries per square centimeter of tissue, the reduction
of FCD after isovolemic hemodilution might be attributable to an
altered microhematocrit. In contrast to hemodilution, the attenuation
of the decrease in FCD after 4 h of ischemia followed by
reperfusion might be due to less capillary endothelial swelling as
verified by electron microscopic analysis.
Different results obtained by various investigators with respect to the efficacy and toxicity of hemoglobin solutions are likely to be explained by the diversity of the solutions used, owing to the process of production and purification. For instance, because of their biological activity, traces of membrane phospholipids that may be contaminants of Hb solutions are known to elicit toxic effects. In support of this view are results described by Rabinovici et al. (23), who were able to prevent toxic effects of liposome-encapsulated hemoglobin by treating recipients of the compound with a platelet-activating factor (PAF) receptor antagonist (23). PAF-like lipids originating from membrane phospholipids can bind to the PAF receptor (28); therefore the effect of the receptor antagonist may be attributable to competitive inhibition of binding of PAF-like lipids to the PAF receptor rather than PAF itself, thus implicating toxic properties of phospholipids remaining in these hemoglobin solutions.
Our results are not in agreement with the paradigm that oxygen-carrying solutions contribute per se to an enhancement of oxygen free radical formation by virtue of providing more oxygen to the tissues. This notion is also supported by findings from Sirsjö et al. (27), who demonstrated that hyperbaric oxygen treatment results in improved FCD and RBC velocity and reduction of I/R injury in striated skin muscle in the same experimental model. Furthermore, several studies have demonstrated that oxygen-carrying blood substitutes do not have a notoriously deleterious impact on I/R injury, as hypothesized by Sadrzadeh et al. (24) and Faassen et al. (5). On the contrary, our findings and those from other studies using DCLHb indicate that because the different characteristics depend on various production and purification procedures, oxygen-carrying solutions have to be clearly defined with regard to purity and consistency for evaluation as potential RBC substitutes.
| |
FOOTNOTES |
|---|
Address for reprint requests: S. Pickelmann, Dept. for Surgery, Klinikum Grosshadern, Munich, Marchioninistr. 15, 81377 Munich, Germany.
Received 24 March 1997; accepted in final form 10 April 1998.
| |
REFERENCES |
|---|
|
|
|---|
1.
Botzlar, A.,
D. Nolte,
and
K. Messmer.
Effects of ultrapurified polymerized bovine hemoglobin on the microcirculation in striated muscle.
Eur. J. Med. Res.
1:
471-478,
1996[Medline].
2.
Chatterjee, R.,
E. V. Welty,
R. Y. Walder,
S. L. Pruitt,
P. H. Rogers,
A. Arnone,
and
J. A. Walder.
Isolation and characterization of a new hemoglobin derivative cross-linked between the alpha chains (99lysine
1-99lysine
2).
J. Biol. Chem.
261:
9929-9937,
1986
3.
Cole, D. J.,
R. M. Schell,
J. C. Drummond,
and
L. Reynolds.
Focal cerebral ischemia in rats. Effect of hypervolemic hemodilution with diaspirin cross-linked hemoglobin versus albumin on brain injury and edema.
Anesthesiology
78:
335-342,
1993[Medline].
4.
Dawidson, I.,
S. Drukker,
B. Hedlund,
D. H. Marks,
and
J. Reisch.
Deleterious effects of stroma-free hemoglobin used in resuscitative fluid for rats with ischemic intestinal shock.
Crit. Care Med.
16:
606-609,
1988[Medline].
5.
Faassen, A. E.,
S. R. Sundby,
S. S. Panter,
R. M. Condie,
and
B. E. Hedlund.
Hemoglobin: a lifesaver and an oxidant. How to tip the balance.
Biomater. Artif. Cells Artif. Organs
16:
93-104,
1988[Medline].
6.
Frankel, L. R.
Diaspirin crosslinked hemoglobin is efficacious in gut resuscitation as measured by a GI tract optode.
J. Trauma
40:
231-241,
1996[Medline].
7.
Freas, W.,
R. Llave,
M. Jing,
J. Hart,
P. McQuillan,
and
S. M. Muldoon.
Contractile effects of diaspirin cross-linked hemoglobin (DCLHb) on isolated porcine blood vessels.
J. Lab. Clin. Med.
125:
762-767,
1995[Medline].
8.
Gulati, A.,
and
A. C. Sharma.
Prazosin blocks the pressor but not the regional circulatory effects of diaspirin crosslinked hemoglobin.
Life Sci.
55:
121-130,
1994[Medline].
9.
Harris, A. G.,
R. Leiderer,
F. Peer,
and
K. Messmer.
Skeletal muscle microvascular and tissue injury after varying durations of ischemia.
Am. J. Physiol.
271 (Heart Circ. Physiol. 40):
H2388-H2398,
1996
10.
Kumar, R.
Effect of diaspirin crosslinked hemoglobin on the brain and kidney perfusion of hemorrhaged rats using laser-doppler flowmeter.
Artif. Cells Blood Substit. Immobil. Biotechnol.
24:
370-371,
1996.
11.
Lübbers, D. W.
The meaning of the tissue oxygenation distribution curve and its measurements by means of Pt electrodes.
Prog. Respir. Res.
3:
112-117,
1969.
12.
McCord, J. M.
Oxygen-derived free radicals in postischemic tissue injury.
N. Engl. J. Med.
312:
159-163,
1985[Abstract].
13.
McKenzie, J. E.,
E. A. Cost,
D. M. Scandling,
N. W. Ahle,
and
R. W. Savage.
Effects of diaspirin crosslinked haemoglobin during coronary angioplasty in the swine.
Cardiovasc. Res.
28:
1188-1192,
1994[Medline].
14.
Menger, M. D.,
F. U. Sack,
J. H. Barker,
G. Feifel,
and
K. Messmer.
Quantitative analysis of microcirculatory disorders after prolonged ischemia in skeletal muscle. Therapeutic effects of prophylactic isovolemic hemodilution.
Res. Exp. Med. (Berl.)
188:
151-165,
1988[Medline].
15.
Menger, M. D.,
D. Steiner,
and
K. Messmer.
Microvascular ischemia-reperfusion injury in striated muscle: significance of "no reflow".
Am. J. Physiol.
263 (Heart Circ. Physiol. 32):
H1892-H1900,
1992
16.
Messmer, K.,
L. Görnandt,
E. Sinagowitz,
L. Sunder-Plassmann,
F. Jesch,
and
M. Kessler.
Local oxygen tension in tissue of different organs during limited normovolemic hemodilution.
Bibl. Anat.
12:
327-332,
1973[Medline].
17.
Motterlini, R.,
R. Foresti,
K. Vandegriff,
M. Intaglietta,
and
R. M. Winslow.
Oxidative-stress response in vascular endothelial cells exposed to acellular hemoglobin solutions.
Am. J. Physiol.
269 (Heart Circ. Physiol. 38):
H648-H55,
1995
18.
Nolte, D.,
A. Botzlar,
S. Pickelmann,
E. Bouskela,
and
K. Messmer.
Effects of diaspirin-cross-linked hemoglobin (DCLHb) on the microcirculation of striated skin muscle in the hamster: a study on safety and toxicity.
J. Lab. Clin. Med.
130:
314-327,
1997[Medline].
19.
Nolte, D.,
M. D. Menger,
and
K. Messmer.
Microcirculatory models of ischemia-reperfusion injury in skin and striated muscle.
Int. J. Microcirc. Clin. Exp.
15:
9-16,
1995.
20.
Nolte, D.,
P. Steinhauser,
S. Berger,
R. Härtl,
S. Pickelmann,
A. Botzlar,
and
K. Messmer.
Effects of diaspirin-cross-linked hemoglobin (DCLHb) on local tissue oxygen tension in striated skin muscle: an efficacy study in the hamster.
J. Lab. Clin. Med.
130:
328-338,
1997[Medline].
21.
Pincemail, J.,
O. Detry,
C. Philippart,
J. O. Defraigne,
C. Franssen,
K. Burhop,
C. Deby,
M. Meurisse,
and
M. Lamy.
Diaspirin crosslinked hemoglobin (DCLHb): absence of increased free radical generation following administration in a rabbit model of renal ischemia and reperfusion.
Free Radic. Biol. Med.
19:
1-9,
1995[Medline].
22.
Powell, C. C.,
S. C. Schultz,
D. G. Burris,
W. R. Drucker,
and
D. S. Malcolm.
Subcutaneous oxygen tension: a useful adjunct in assessment of perfusion status.
Crit. Care Med.
23:
867-873,
1995[Medline].
23.
Rabinovici, R.,
A. S. Rudolph,
T. L. Yue,
and
G. Feuerstein.
Biological responses to liposome-encapsulated hemoglobin (LEH) are improved by a PAF antagonist.
Circ. Shock
31:
431-445,
1990[Medline].
24.
Sadrzadeh, S. M.,
E. Graf,
S. S. Panter,
P. E. Hallaway,
and
J. W. Eaton.
Hemoglobin. A biologic fenton reagent.
J. Biol. Chem.
259:
14354-14356,
1984
25.
Schultz, S. C.,
B. Grady,
F. Cole,
I. Hamilton,
K. Burhop,
and
D. S. Malcolm.
A role for endothelin and nitric oxide in the pressor response to diaspirin cross-linked hemoglobin.
J. Lab. Clin. Med.
122:
301-308,
1993[Medline].
26.
Sharma, A. C.,
and
A. Gulati.
Yohimbine modulates diaspirin crosslinked hemoglobin-induced systemic hemodynamics and regional circulatory effects.
Crit. Care Med.
23:
874-884,
1995[Medline].
27.
Sirsjö, A.,
H. A. Lehr,
D. Nolte,
T. Haapaniemi,
D. H. Lewis,
G. Nylander,
and
K. Messmer.
Hyperbaric oxygen treatment enhances the recovery of blood flow and functional capillary density in postischemic striated muscle.
Circ. Shock
40:
9-13,
1993[Medline].
28.
Snyder, F.
Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators.
Am. J. Physiol.
259 (Cell Physiol. 28):
C697-C708,
1990
29.
Tsai, A. G.,
B. Friesenecker,
R. M. Winslow,
and
M. Intaglietta.
Functional capillary density changes during blood substitution with alpha alpha Hb and dextran 70: influence on oxygen delivery.
Artif. Cells Blood Substit. Immobil. Biotechnol.
22:
841-847,
1994[Medline].
This article has been cited by other articles:
![]() |
D. Erni, R. Wettstein, S. Schramm, C. Contaldo, H. Sakai, S. Takeoka, E. Tsuchida, M. Leunig, and A. Banic Normovolemic hemodilution with Hb vesicle solution attenuates hypoxia in ischemic hamster flap tissue Am J Physiol Heart Circ Physiol, May 1, 2003; 284(5): H1702 - H1709. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kleen, O. Habler, F. Meisner, G. Kemming, A. Pape, and K. Messmer Effects of primary resuscitation from shock on distribution of myocardial blood flow J Appl Physiol, February 1, 2000; 88(2): 373 - 385. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. von Dobschuetz, T. Hoffmann, C. Engelschalk, and K. Messmer Effect of diaspirin cross-linked hemoglobin on normal and postischemic microcirculation of the rat pancreas Am J Physiol Gastrointest Liver Physiol, June 1, 1999; 276(6): G1507 - G1514. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |